Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)

NCT00959439 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis
Osteoarthritis

Interventions

DRUG: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
DRUG: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)

Sponsor

Sandoz